查看購物車
  • Simplified Chinese
  • Japanese
  • Korean
體外診斷檢測流程概況：第七版（2025-2030）
市場調查報告書
商品編碼
1844742

體外診斷檢測流程概況：第七版（2025-2030）

IVD Test Procedure Volumes, 7th Edition (2025-2030)
出版日期: | 出版商: Kalorama Information | 英文 275 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

受次世代定序 (NGS)、微流控和精準醫療等領域強勁技術進步的推動，全球體外診斷 (IVD) 市場將在 2025 年繼續擴張，並將診斷轉變為更個人化、以患者為中心的領域。 "體外診斷檢測流程概覽：第七版（2025-2030）" 對全球檢測趨勢進行了全面、數據驅動的分析，是對 Kalorama Information 旗艦出版物 "體外診斷 (IVD) 檢測市場：第十八版（2025-2030）" 的重要補充。

量化全球檢測格局

本報告深入分析了體外診斷 (IVD) 在主要檢測類別中的應用，包括分子診斷、臨床化學、免疫分析、血液學、凝血、微生物學、血庫和組織學/細胞學。報告還量化了主要全球市場的檢測數量、平均單次檢測成本和區域差異。報告預測了到 2030 年的發展趨勢，並深入分析了影響全球診斷市場的檢測利用趨勢、成本趨勢以及不斷變化的區域檢測模式。

技術進步重塑診斷

隨著 IVD 產業擺脫疫情驅動的需求，包括自我檢測、居家診斷和即時檢測 (POC) 解決方案在內的新模式正在加速普及，並重塑醫療保健服務模式。

同時，分子診斷和癌症診斷的成長印證了該領域對早期檢測和透過液體活檢及基因組檢測進行非侵入性監測的關注。這些進展與全球精準醫療的發展趨勢相符，但也帶來了與成本、監管和公平取得相關的新挑戰。

應對經濟和監管壓力

本報告將這些市場推動因素置於快速變化的監管和經濟環境中進行分析。面對歐盟體外診斷醫療器材法規 (IVDR) 和不斷變化的美國食品藥物管理局 (FDA) 框架下日益嚴格的審查，製造商必須應對複雜的審批流程，同時還要應對影響報銷和應用的支付方壓力。技術進步、可負擔性和可擴展性之間的平衡將決定體外診斷 (IVD) 發展的下一階段。

研究方法與策略價值

本研究方法是 Kalorama 獨有的，能夠提供準確、透明且可操作的體外診斷藥物生產和銷售估算。這使高階主管、策略家和投資者能夠對標績效、識別成長機會，並使產品組合與新興診斷趨勢保持一致。

體外診斷決策者必備的資源

對於希望了解體外診斷 (IVD) 市場發展方向以及未來五年 IVD 需求將如何推動創新、投資和市場准入的公司而言， "體外診斷檢測程序量，第 7 版 (2025-2030)" 是策略決策的必備資源。

目錄

第一章：摘要整理

  • 體外診斷檢測量估算與預測
  • 範圍與研究方法

第二章：引言

  • 範圍
  • 概述
  • 產業趨勢
  • 人口趨勢
    • 全球人口與老化
    • 勞動力減少
  • 慢性病增加
  • 個人化醫療
  • 嚴重疾病威脅
    • 蜱傳疾病 (TBD)
    • 寨卡病毒
    • 恰加斯病
    • 登革熱
    • 伊波拉病毒
    • 基孔肯雅病毒
    • 中東呼吸道症候群冠狀病毒 (MERS-CoV)
    • 馬堡病毒
    • 猴痘
  • 新興國家與市場

第三章 體外診斷 (IVD) 檢測領域

  • 體外診斷 (IVD) 檢測趨勢
  • 區隔市場成長預測
    • 即時偵測 (POC)偵測
    • 臨床化學
    • 免疫分析
    • 質譜分析（免疫學）
    • 分子檢測
    • 血液學
    • 凝血
    • 傳統微生物學
    • 血型鑑定
    • 組織學/細胞學
  • 區隔產品銷售

第四章 全球體外診斷市場

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 墨西哥和南美洲
    • 巴西
    • 墨西哥
    • 其他國家和地區
    • 阿根廷
    • 智利
    • 哥倫比亞
    • 秘魯
    • 委內瑞拉
    • 其他國家和地區地區
  • 西歐
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他國家和地區
    • 奧地利
    • 比利時
    • 丹麥
    • 芬蘭
    • 希臘
    • 愛爾蘭
    • 挪威
    • 荷蘭
    • 葡萄牙
    • 瑞典
    • 瑞士
    • 其他國家和地區
  • 東歐
    • 俄羅斯
    • 東歐其他國家
    • 捷克
    • 匈牙利
    • 波蘭
    • 羅馬尼亞
    • 烏克蘭
    • 其他國家
  • 亞洲太平洋
    • 中國
    • 日本
    • 其他國家和地區
    • 澳大利亞
    • 香港
    • 印度
    • 印尼
    • 馬來西亞
    • 巴基斯坦
    • 菲律賓
    • 新加坡
    • 韓國
    • 台灣
    • 泰國
    • 越南
    • 紐西蘭
    • 其他國家和地區
  • 中東
    • 土耳其
    • 其他中東國家
    • 伊朗
    • 伊拉克
    • 以色列
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他國家
  • 非洲
    • 奈及利亞
    • 南非
    • 其他國家區域

第五章 即時檢驗 (POC) 流程

  • 範圍
  • 引言
    • 即時檢定 (POC) 概述
  • 全球 POC 偵測量（依檢測類型劃分）
  • POC 自測
  • POC 自測產品銷售
  • 價格趨勢
  • POC 專業偵測
  • POC 體外診斷 (IVD) 產品銷售
  • 價格趨勢

第六章：臨床化學檢測流程

  • 範圍
  • 引言
  • 檢測類型
  • 普通化學
  • 酶
  • 葡萄糖
  • 脂質
  • 蛋白質
  • 其他化合物
  • 血氣和電解質
  • 尿液檢測
  • 全球臨床化學產品銷售
  • 價格趨勢

    第七章 免疫測定

    • 範圍
    • 引言
    • 標記技術
      • 酵素免疫測定
      • 化學發光磁珠免疫測定 (CMIA)
      • 螢光偏光免疫測定 (FPIA)
      • 放射免疫測定法 (RIA)
    • 檢測技術與產品銷售
      • 心臟標記
      • 腫瘤標記
      • 自體免疫疾病
      • 過敏症狀
      • 甲狀腺疾病
      • 蛋白質
      • 阿茲海默症疾病
      • 貧血
      • 不孕症檢測
      • 治療藥物監測
      • 維生素D
      • 糖尿病/糖化血紅素
      • 濫用藥物
      • 傳染病
    • 設備
    • 價格趨勢

    第八章 分子偵測程序

    • 引言
    • 檢測類型
      • 檢測技術
      • 傳染病
      • 血液檢測
      • 癌症
      • 移植配對
      • 血栓形成相關單核苷酸多態性（SNP）
      • 遺傳性疾病
      • 其他分子檢測
      • 產前檢測
    • 分子體外診斷（IVD）產品全球銷售額
    • 價格趨勢

    第九章：實驗室血液學檢測程序

    • 範圍
    • 引言
    • 檢測類型
    • 血液學產品的全球銷售額
    • 價格趨勢

    第十章：凝血檢測程序

    • 引言
    • 檢測類型
    • 凝血產品的全球銷售額
    • 價格趨勢

    第十一章：微生物學檢測技術

    • 範圍
    • 引言
    • 檢測類型
      • 自動化鑑定/藥敏試驗試劑盒及試劑
      • 手動試劑盒及試劑
      • 血液培養
      • 顯色培養基
      • 快速微生物學檢測檢測
      • 質譜分析
    • 傳統體外診斷微生物產品的全球銷售額
      • 鑑定/藥敏試驗試劑盒及試劑
      • 血液培養
      • 顯色培養基
      • 快速微生物檢測
      • 質譜分析
    • 價格趨勢

    第十二章：血型鑑定技術

    • 引言
    • 檢測類型
    • 血型鑑定產品銷售
    • 價格趨勢

    第十三章：組織學/細胞學檢測程序

    • 範圍
    • 引言
    • 檢測類型
      • 免疫組織化學檢測
      • 原位雜交檢測項目
      • 巴氏抹片檢查
      • 傳統非巴氏染色
      • 循環腫瘤細胞
      • 流式細胞儀
    • 組織學/細胞學體外診斷產品銷售
    • 價格趨勢

    第十四章：公司簡介

    • 引言
    • ABBOTT DIAGNOSTICS
    • AGILENT TECHNOLOGIES
    • BECTON, DICKINSON AND COMPANY (BD)
    • BIOMERIEUX INC.
    • BIO-RAD LABORATORIES, INC.
    • DANAHER CORPORATION
    • DEXCOM
    • DIASORIN
    • EXACT SCIENCES
    • HOLOGIC, INC.
    • ILLUMINA
    • NATERA
    • QUIDELORTHO CORPORATION
    • REVVITY
    • ROCHE DIAGNOSTICS
    • SIEMENS HEALTHINEERS (SIEMENS)
    • SYSMEX CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • WERFEN
    • 簡介目錄
    Product Code: 25-025KA

    The global in vitro diagnostics (IVD) market continues to expand in 2025, driven by powerful innovations in next-generation sequencing (NGS), microfluidics, and precision medicine that are transforming diagnostics into a more personalized, patient-centric field. "IVD Test Procedure Volumes, 7th Edition (2025-2030)" provides a comprehensive, data-driven analysis of global test volume trends, serving as a critical companion to Kalorama Information's flagship publication, "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 18th Edition (2025-2030)".

    Quantifying the Global Testing Landscape

    This report delivers an in-depth examination of IVD procedures across major testing categories-including molecular diagnostics, clinical chemistry, immunoassays, hematology, coagulation, microbiology, blood banking, and histology/cytology. It quantifies the number of tests performed, the average cost per procedure, and regional variations across key markets worldwide. With forecasts extending through 2030, the study offers essential insight into test utilization trends, cost dynamics, and evolving regional testing patterns that are shaping the global diagnostics landscape.

    Technological Advancements Reshaping Diagnostics

    As the IVD industry evolves beyond pandemic-driven demand, new paradigms in self-testing, home-based diagnostics, and point-of-care (POC) solutions are accelerating accessibility and reshaping healthcare delivery. Meanwhile, growth in molecular and cancer diagnostics underscores the sector's pivot toward early detection and non-invasive monitoring through liquid biopsy and genomic testing. These advancements align with the global push toward precision medicine-but also introduce new challenges related to cost, regulation, and equitable access.

    Navigating Economic and Regulatory Pressures

    This report contextualizes these market drivers within a rapidly changing regulatory and economic environment. With rising scrutiny under the EU's IVDR and FDA's evolving frameworks, manufacturers must navigate complex approval pathways while addressing payer pressures that impact reimbursement and adoption. The balance between technological advancement, affordability, and scalability will define the next stage of IVD growth.

    Methodology and Strategic Value

    Drawing on Kalorama's proprietary methodologies, this study presents accurate, transparent, and actionable estimates of IVD procedure volumes and revenues-empowering executives, strategists, and investors to benchmark performance, identify growth opportunities, and align product portfolios with emerging diagnostic trends.

    An Essential Resource for IVD Decision-Makers

    For organizations seeking to understand where the IVD market is headed-and how procedural demand will drive innovation, investment, and access over the next five years-"IVD Test Procedure Volumes, 7th Edition (2025-2030)" is an indispensable resource for strategic decision-making.

    TABLE OF CONTENTS

    CHAPTER ONE: EXECUTIVE SUMMARY

    • IVD PROCEDURE VOLUME ESTIMATE AND FORECAST
      • Figure 1-1: Global IVD Procedure Volumes, 2025 and 2030 (in millions # volume)
    • SCOPE & METHODOLOGY

    CHAPTER TWO: INTRODUCTION

    • SCOPE
    • OVERVIEW
    • INDUSTRY TRENDS
      • Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2025-2030 (in millions # volume; $ million)
    • DEMOGRAPHIC TRENDS
      • Global Population and Aging
        • Figure 2-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
        • Figure 2-2: Global Population Distribution, 2022
        • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 [Australia, Brazil, Canada, China, China (Hong Kong SAR), France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, Singapore, South Africa, Spain, Turkey, United Kingdom, United States, World]
      • Workforce Reduction
        • Table 2-3: WHO Model List of Essential In Vitro Diagnostics (EDL)
    • INCREASE IN CHRONIC DISEASES
      • Figure 2-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)
    • PERSONALIZED MEDICINE
    • HIGH-CONSEQUENCE DISEASE THREATS
      • Table 2-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats
      • Tickborne Diseases (TBDs)
      • Zika
      • Chagas
      • IVD Vendors Active in Chagas Diagnostics
      • Dengue
      • Ebola
      • Chikungunya
      • Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
      • Marburg
      • Monkeypox
    • EMERGING AND EMERGED MARKETS
      • Table 2-5: Developed/Developing Economies, UN Classification*, 2025
      • Figure 2-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
      • Where Are the Best Markets?
        • Table 2-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 [Australia, Brazil, China, France, Germany, Hungary, India, Mexico, Netherlands, Peru, Poland, Romania, Saudi Arabia, South Africa, South Korea, Sweden, Switzerland, Turkey, United Kingdom, United States]
      • Economic Growth and the Expanding Middle Class

    CHAPTER THREE: IVD TESTING SEGMENTS

    • IVD TESTING TRENDS
      • Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
    • SEGMENT GROWTH PROJECTIONS
      • Point-of-Care (POC) Testing
      • Clinical Chemistry
      • Immunoassays
      • Mass Spectrometry (Immuno)
      • Molecular Assays
      • Hematology
      • Coagulation
      • Conventional Microbiology
      • Blood Grouping/Typing
      • Histology/Cytology
    • SEGMENT PRODUCT SALES
      • Table 3-5: IVD Product Sales including Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-6: IVD Product Sales including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-7: IVD Product Sales excluding Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
      • Table 3-8: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]

    CHAPTER FOUR: GLOBAL IVD MARKETS

    • GENERAL
      • Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2025-2030 (millions) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
      • Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2025-2030 (%) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
    • NORTH AMERICA
      • United States
      • Canada
    • MEXICO, CENTRAL, & SOUTH AMERICA
      • Brazil
      • Mexico
      • Other Central & South America
      • Argentina
      • Chile
      • Colombia
      • Peru
      • Venezuela
      • All Other Countries & Territories
    • WESTERN EUROPE
      • France
      • Germany
      • Italy
      • Spain
      • United Kingdom
      • Other Western Europe
      • Austria
      • Belgium
      • Denmark
      • Finland
      • Greece
      • Ireland
      • Norway
      • Netherlands
      • Portugal
      • Sweden
      • Switzerland
      • All Other Countries & Territories
    • EASTERN EUROPE
      • Russia
      • Other Eastern Europe
      • Czech Republic
      • Hungary
      • Poland
      • Romania
      • Ukraine
      • All Other Countries
    • ASIA/PACIFIC
      • China
      • Japan
      • Other Asian Countries and Territories
      • Australia
      • Hong Kong
      • India
      • Indonesia
      • Malaysia
      • Pakistan
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
      • New Zealand
      • All Other Countries & Territories
    • MIDDLE EAST
      • Turkey
      • Other Middle East
      • Iran
      • Iraq
      • Israel
      • Saudi Arabia
      • United Arab Emirates
      • All Other Countries
    • AFRICA
      • Nigeria
      • South Africa
      • All Other Countries & Territories

    CHAPTER FIVE: POINT-OF-CARE (POC) PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Point-of-Care (POC) Testing Overview
    • GLOBAL POC PROCEDURE VOLUME BY TEST TYPE
      • Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2025-2030
      • Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2025-20230
      • Figure 5-1: Regional POC Procedure Volumes including blood glucose tests, 2025 [Europe, Japan, United States, Rest of World]
    • POC SELF TESTS
      • Table 5-3: POC Self-Test Procedural Volume, by Type, 2025-2030 (millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
      • Traditional Blood Glucose Monitoring Activities
      • Continuous Blood Glucose Monitoring
      • Pregnancy and Fertility Testing
      • Coagulation Testing
      • Fecal Occult Blood Testing
      • Drugs of Abuse Testing
      • H. pylori Testing
      • HIV Testing
      • Infectious Disease
      • Cholesterol Testing
      • POC Urinalysis Testing
      • Other POC Self-Testing
    • POC SELF-TESTING PRODUCT SALES
      • Table 5-4: POC Self-Test Product Sales, by Type, 2025-2030 ($ million) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
    • PRICING TRENDS
      • Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2025-2030 [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
    • POC PROFESSIONAL TESTING
      • Table 5-6: POC Professional Procedural Volume, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
      • POC Professional Blood Glucose Testing Procedures
      • POC Professional Critical Care Testing
      • POC Fertility Testing
      • POC Professional Infectious Disease Testing
      • POC Professional Cardiac Marker Testing
      • POC Professional Cholesterol/Lipid Testing
      • POC Professional Coagulation Testing
      • POC Professional HbA1C Testing
      • POC Professional Hematology Testing
      • POC Professional Fecal Occult Blood Screening
      • POC Professional Drugs of Abuse Testing
      • POC Professional Urinalysis Testing
      • Other POC Professional Testing
    • POC IVD PRODUCT SALES
      • Table 5-7: POC Professional IVD Product Sales, by Type, 2025-2030 ($ million) [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
    • PRICING TRENDS
      • Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

    CHAPTER SIX: CLINICAL CHEMISTRY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
      • Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
      • General Chemistry
      • Enzymes
      • Glucose
      • Lipids
      • Proteins
      • Other Compounds
      • Blood Gases & Electrolytes
      • Urinalysis
    • GLOBAL SALES OF CLINICAL CHEMISTRY PRODUCTS
      • Table 6-2: Clinical Chemistry Product Sales, by Type, 2025-2030 ($ million) [Blood Gas Analysis, General Chemistry, Urinalysis]
    • PRICING TRENDS
      • Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]

    CHAPTER SEVEN: IMMUNOASSAY PROCEDURES

    • SCOPE
    • INTRODUCTION
    • LABELING TECHNIQUES
      • Enzyme Immunoassays
      • Chemiluminescent Magnetic Immunoassays (CMIAs)
      • Fluorescence Polarization Immunoassays (FPIAs)
      • Radioimmunoassays (RIAs)
        • Table 7-1: Immunoassay Procedural Volume, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
        • Figure 7-1: Regional Immunoassay Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TESTING PROCEDURES & PRODUCT SALES
      • Table 7-2: Immunoassay Product Sales, by Type, 2025-2030 ($ million) [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
      • Cardiac Markers
      • Tumor Markers
      • Autoimmune Conditions
      • Allergy Conditions
      • Thyroid Conditions
      • Proteins
      • Alzheimer's Disease
      • Anemia
      • Fertility Testing
      • Therapeutic Drug Monitoring
      • Vitamin D
      • Diabetes/HbA1c
      • Drugs of Abuse
      • Infectious Diseases
        • Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2025-2030 [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
        • Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
    • INSTRUMENTS
    • PRICING TRENDS
      • Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]

    CHAPTER EIGHT: MOLECULAR TESTING PROCEDURES

    • INTRODUCTION
      • Table 8-1: Molecular Assay Procedural Volume, by Type, 2025-2030 (millions) [Molecular - Other, Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Non Cancer, Molecular Histology - Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
      • Figure 8-1: Regional Molecular Assay Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
      • Testing Technologies
      • Infectious Diseases
        • Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2025-2030 [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
      • Blood Screening
      • Cancer
      • Transplant Matching
      • Thrombophilia SNPs
      • Inherited Diseases
      • Other Molecular Tests
      • Prenatal
    • GLOBAL SALES OF MOLECULAR IVD PRODUCTS
      • Table 8-3: Molecular Assay Product Sales, by Type, 2025-2030 ($ million) [Genetic Testing/Inherited Disease, Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - Cancer, Molecular Histology - Non Cancer, Molecular HPV, Molecular Infectious disease, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Other Molecular, Prenatal]
      • Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
    • PRICING TRENDS
      • Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2025-2030 [Molecular Assays - Oncology, Molecular Blood bank, Molecular Histology - cancer, Molecular Histology - non cancer, Molecular HPV, Molecular Infectious disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Prenatal]

    CHAPTER NINE: LABORATORY-BASED HEMATOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
      • Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
    • TYPES OF TESTS
    • GLOBAL SALES OF HEMATOLOGY PRODUCTS
      • Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2025-2030 ($ million) [Complete Blood Count, Other Hematology Tests]
    • PRICING TRENDS
      • Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]

    CHAPTER TEN: COAGULATION TESTING PROCEDURES

    • INTRODUCTION
      • Table 10-1: Coagulation Procedural Volume, 2025-2030 [D-dimer, PT/INR]
      • Figure 10-1: US/ROW Coagulation Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
    • GLOBAL SALES OF COAGULATION PRODUCTS
      • Table 10-2: Coagulation Product Sales, 2025-2030 ($ million) (D-dimer, PT/INR)
    • PRICING TRENDS
      • Table 10-3: Coagulation $ Products per Procedure, 2025-2030 [D-dimer, PT/INR]

    CHAPTER ELEVEN: MICROBIOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
    • TYPES OF TESTS
      • ID/AST Automated Panels & Reagents
      • Manual Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
    • GLOBAL SALES OF CONVENTIONAL IVD MICROBIOLOGY PRODUCTS
      • ID/AST Panels & Reagents
      • Blood Culture
      • Chromogenic Media
      • Rapid Microbiological Tests
      • Mass Spectrometry
        • Table 11-2: Conventional Microbiology Product Sales, by Type, 2025-2030 ($ million) [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
    • PRICING TRENDS
      • Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]

    CHAPTER TWELVE: BLOOD GROUPING/TYPING PROCEDURES

    • INTRODUCTION
      • Table 12-1: Blood Grouping/Typing Procedure Volumes, 2025-2030
      • Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
    • BLOOD GROUPING/TYPING PRODUCT SALES
      • Table 12-2: Blood Grouping/Typing Product Sales, 2025-2030 ($ million)
    • PRICING TRENDS
      • Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2025-2030

    CHAPTER THIRTEEN: HISTOLOGY/CYTOLOGY PROCEDURES

    • SCOPE
    • INTRODUCTION
      • Table 13-1: Histology/Cytology Procedural Volume, by Type, 2025-2030 [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
      • Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
    • TYPES OF TESTS
      • Immunohistochemistry Tests
      • In Situ Hybridization Tests
      • Pap Tests
      • Traditional Non-Pap Stains
      • Circulating Tumor Cells
      • Flow Cytometry
    • HISTOLOGY/CYTOLOGY IVD PRODUCT SALES
      • Table 13-2: Histology/Cytology Product Sales, by Type, 2025-2030 ($ million) [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
    • PRICING TRENDS
      • Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2025-2030

    CHAPTER FOURTEEN: COMPANY PROFILES

    • INTRODUCTION
      • Table 14-1: Revenues of Selected Top 20 IVD Companies, 2024 and estimated 2025 ($ million) [Abbott Diagnostics, Agilent, Becton Dickinson, bioMerieux, Bio-Rad Laboratories, Bruker - CALID, Danaher, Dexcom, Diasorin, Exact Sciences, Hologic, Illumina, Natera, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen]
    • ABBOTT DIAGNOSTICS
      • Recent Revenue History
        • Table 14-2: Abbott Diagnostic Revenues, 2022-2024 ($ million)
        • Table 14-3: Abbott Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
    • AGILENT TECHNOLOGIES
      • Recent Revenue History
        • Table 14-4: Agilent Revenues, 2022-2024 (million $)
    • BECTON, DICKINSON AND COMPANY (BD)
      • Recent Revenue History
        • Table 14-5: BD Diagnostic Revenues, 2022-2024 (million $) FYE Sept 30
    • BIOMERIEUX INC.
      • Recent Revenue History
        • Table 14-6: bioMerieux IVD Revenues, 2022-2024 (Euro million)
    • BIO-RAD LABORATORIES, INC.
      • Recent Revenue History
        • Table 14-7: Bio-Rad Diagnostics Revenues, 2022-2024 ($ million)
    • DANAHER CORPORATION
      • Recent Revenue History
        • Table 14-8: Danaher Global IVD Diagnostic Sales, 2022-2024 ($ million)
    • DEXCOM
      • Recent Revenue History
        • Table 14-9: Dexcom IVD Diagnostic Sales, 2022-2024 ($ million)
    • DIASORIN
      • Recent Revenue History
        • Table 14-10: Diasorin Revenues, 2022-2024 (million Euro )
    • EXACT SCIENCES
      • Recent Revenue History
        • Table 14-11: Exact Sciences Revenues, 2022-2024 ($ million)
    • HOLOGIC, INC.
      • Recent Revenue History
        • Table 14-12: Hologic Revenues, 2022-2024 ($ million)
    • ILLUMINA
      • Recent Revenue History
        • Table 14-13: Illumina Diagnostics Revenues, 2022-2024 ($ million)
      • Recent Revenue History
        • Table 14-14: Mindray Revenue History, 2022-2024 (billion CNY)
    • NATERA
      • Recent Revenue History
        • Table 14-15: Natera Revenue History, 2022-2024 ($ million)
    • QUIDELORTHO CORPORATION
      • Recent Revenue History
        • Table 14-16: QuidelOrtho Revenue History, 2022-2024 ($ million)
        • Table 14-17: QuidelOrtho Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
    • REVVITY
      • Table 14-18: Revvity Revenue History, 2022-2024 ($ million, estimated)
    • ROCHE DIAGNOSTICS
      • Recent Revenue History
        • Table 14-19: Roche Diagnostics IVD Revenues, 2022-2024 (CHF million)
        • Table 14-20: Roche Diagnostic Revenues, by Segment, 2023-2024 (CHF million)
    • SIEMENS HEALTHINEERS (SIEMENS)
      • Recent Revenue History
        • Table 14-21: Siemens Healthineers IVD Revenues, 2022-2024 (Euro million)
    • SYSMEX CORPORATION
      • Recent Revenue History
        • Table 14-22: Sysmex IVD Revenues, 2022-2024 (FY March 31) (billions of yen)
        • Table 14-23: Sysmex Diagnostic Revenues, by Segment, 2022-2024 (billions of yen)
    • THERMO FISHER SCIENTIFIC INC.
      • Recent Revenue History
        • Table 14-24: Thermo Fischer IVD Revenues, 2022-2024 ($ million)
    • WERFEN
      • Recent Revenue History
        • Table 14-25: Werfen IVD Revenues, 2022-2024 (Euro billion)